X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

March 31, 2026

Conditions
Advanced Solid Tumor Cancer
Interventions
COMBINATION_PRODUCT

X-PACT

X-PACT is comprised of a phosphor device, the drug methoxsalen sterile solution and X-ray energy. The dose of methoxsalen sterile solution per injection will vary per patient and will remained fixed across injections within each patient as it is based on the applicable tumor volume at baseline. Immediately after each injection of the combination product, patients will be exposed to an X-ray beam delivered via a LINAC (and thus targeted at the tumor) at a fixed dose to activate the combination product.

Trial Locations (4)

20016

RECRUITING

Sibley Hospital - Johns Hopkins University, Washington D.C.

27710

RECRUITING

Duke University, Durham

28204

RECRUITING

Levine Cancer Institute, Charlotte

29605

RECRUITING

Prisma Health, Greenville

All Listed Sponsors
lead

Immunolight, LLC

INDUSTRY